Team Science Contact Home

Press Releases
Stromedix secures broad patent coverage for lead program
MORE (PDF) >

Stromedix receives orphan drug designation for STX-100 in chronic allograft nephropathy
MORE (PDF) >

Stromedix raises $25 million in a Series B financing round
MORE (PDF) >

Stromedix in the news

Bio-IT World
GO >

Mass High Tech
GO >

Xconomy.com
GO >

In Vivo Blog
GO >

BioCentury
GO >

x

x Company Fact Sheet
Download our Company Fact Sheet for information on who we are and what we do.
DOWNLOAD (PDF) >



x

Follow Stromedix on Twitter
GO >

 

 
STX-100 is Stromedix’s first clinical candidate and is being developed for the treatment of interstitial fibrosis and tubular atrophy in kidney transplant recipients and for idiopathic pulmonary fibrosis.

x Humanized monoclonal antibody to integrin αvβ6
x Completed phase 1 clinical testing
x Provides localized, injury-specific inhibition of TGF-β activation
x Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease
x Broad therapeutic utility in chronic organ failure, acute organ failure and cancer